Evidence map›Paper›PMID 24782526›Full record

ArticleNucleic acids research2014

A programmable method for massively parallel targeted sequencing.

Erik S Hopmans, Georges Natsoulis, John M Bell, Susan M Grimes, Weiva Sieh, Hanlee P Ji

Abstract read
In one paragraph

Article in Nucleic acids research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Erik S HopmansStanford Genome Technology Center, Stanford University, Palo Alto, CA 94304, USA.
Georges NatsoulisDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
John M BellStanford Genome Technology Center, Stanford University, Palo Alto, CA 94304, USA.
Susan M GrimesDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Weiva SiehDepartment of Health Research and Policy, Stanford University School of Medicine, 259 Campus Drive, Stanford, CA 94305, USA.
Hanlee P JiStanford Genome Technology Center, Stanford University, Palo Alto, CA 94304, USA Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA genomics_ji@stanford.edu.

Funding

WHOLE YEAST GENOME TRANSCRIPTIONAL AND FUNCTIONAL GENE MAPS--A FEASIBILITY STUDYP01HG000205 · NHGRI · STANFORD UNIVERSITY · PI HOWE, ROGER THOMAS, JI, HANLEE P · 1990 to 2016
$120.9M
Statistical Models for Genome Sequencing and AssociationR01HG006137 · NHGRI · UNIVERSITY OF PENNSYLVANIA · PI JI, HANLEE P, ZHANG, NANCY R · 2011 to 2022
$4.3M
Oligonucleotide-Selective Sequencing for integrated and rapid cancer genome analyR33CA174575 · NCI · STANFORD UNIVERSITY · PI JI, HANLEE P · 2013 to 2015
$1.1M
Genetic Epidemiology of Ovarian and Prostate CancerK07CA143047 · NCI · STANFORD UNIVERSITY · PI SIEH, WEIVA · 2010 to 2014
$867k
Mutation Analysis Of Paraffin-Embedded Tumors With Next Generation SequencingR21CA140089 · NCI · STANFORD UNIVERSITY · PI JI, HANLEE P · 2010 to 2011
$378k
Howard Hughes Medical InstituteNCI NIH HHS 1R33CA174575NCI NIH HHS K07CA143047NCI NIH HHS R21 CA140089NCI NIH HHS R33 CA174575NHGRI NIH HHS P01 HG000205NHGRI NIH HHS P01HG000205NHGRI NIH HHS R01 HG006137
6 · The paper itself

Abstract

We have developed a targeted resequencing approach referred to as Oligonucleotide-Selective Sequencing. In this study, we report a series of significant improvements and novel applications of this method whereby the surface of a sequencing flow cell is modified in situ to capture specific genomic regions of interest from a sample and then sequenced. These improvements include a fully automated targeted sequencing platform through the use of a standard Illumina cBot fluidics station. Targeting optimization increased the yield of total on-target sequencing data 2-fold compared to the previous iteration, while simultaneously increasing the percentage of reads that could be mapped to the human genome. The described assays cover up to 1421 genes with a total coverage of 5.5 Megabases (Mb). We demonstrate a 10-fold abundance uniformity of greater than 90% in 1 log distance from the median and a targeting rate of up to 95%. We also sequenced continuous genomic loci up to 1.5 Mb while simultaneously genotyping SNPs and genes. Variants with low minor allele fraction were sensitively detected at levels of 5%. Finally, we determined the exact breakpoint sequence of cancer rearrangements. Overall, this approach has high performance for selective sequencing of genome targets, configuration flexibility and variant calling accuracy.

Indexed as

AllelesChromosome BreakpointsDNA PrimersGenome, HumanGenomicsGenomic Structural VariationHigh-Throughput Nucleotide SequencingHumansMutationNeoplasmsPolymorphism, Single NucleotideSequence Analysis, DNADNA Primers

Identifiers

PMID24782526
PMCPMC4041455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.